Taisho-controlled pharma giant DHG posts 9.4% net profit surge in 2025

DHG Pharmaceutical JSC (HoSE: DHG), one of the leading pharmaceutical firms in Vietnam, reported audited net profit of VND852 billion ($32.35 million) in 2025, down 5% from its pre-audit figure, as additional tax obligations and provisions weighed on earnings.

After audit adjustments, net profit still rose 9.4% compared to 2024’s VND779 billion ($29.58 million), reflecting steady demand in Vietnam’s pharmaceutical market despite rising regulatory and compliance costs.

According to the audited financial statements, the company recorded net revenue of VND5.27 trillion ($199.97 million), unchanged from earlier disclosures, while gross profit reached VND2.51 trillion ($95.14 million), down slightly by VND6 billion ($227,800).

Despite the downward adjustment, the firm exceeded the year’s profit target by 5%, underscoring resilient operating performance.

The audit highlighted the impact of the parliament’s Resolution 107/2023/QH15, which introduces a 15% global minimum corporate tax rate for large multinational-backed firms.

With Japan’s Taisho Pharmaceutical holding a controlling 51.01% stake, DHG had previously benefited from preferential tax rates below the 15% threshold. This triggered additional tax liabilities under the new mechanism.

As a result, the company booked VND33.01 billion ($1.25 million) in additional corporate tax for 2025, VND21.98 billion ($834,500) in back payments for 2024, and VND1.4 billion ($53,150) paid on behalf of Taisho Vietnam.

Beyond tax adjustments, DHG increased provisions related to environmental obligations. The company set aside an additional VND38.1 billion ($1.45 million) for site restoration and cleanup, bringing total long-term provisions for this purpose to VND81.46 billion ($3.09 million) by end-2025. It also recorded VND4 billion ($151,870) in short-term expenses tied to recycling and packaging treatment.

Separately, total revenue from sales and services surpassed VND6 trillion ($222.8 million) for the first time, reaching VND6.14 trillion ($233 million), up more than 7% year-on-year.

DHG shares ended up 0.3% to VND100,100 ($3.8) each on Tuesday.

  • Related Posts

    TG SAFE drug wing raids medical shop in Sangareddy, seizes illegal tramadol worth Rs. 58,904

    In a swift enforcement action against the unauthorized distribution of habit-forming medications, officials from the Drug Control Wing under the Telangana Standards Authority for Food and Essential Drugs (TG SAFE)…

    FDA cancels wholesale drug sales license of Cipla Pharma & Life sciences Ltd

    According to the FDA commissioner, the aim of the FDA is not merely to take regulatory action, but to ensure the safety and quality of medicines and statutory compliance throughout…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    TG SAFE drug wing raids medical shop in Sangareddy, seizes illegal tramadol worth Rs. 58,904

    TG SAFE drug wing raids medical shop in Sangareddy, seizes illegal tramadol worth Rs. 58,904

    FDA cancels wholesale drug sales license of Cipla Pharma & Life sciences Ltd

    FDA cancels wholesale drug sales license of Cipla Pharma & Life sciences Ltd

    At least five workers killed in boiler explosion at pharma unit in Andhra Pradesh’s Sri City SEZ

    At least five workers killed in boiler explosion at pharma unit in Andhra Pradesh’s Sri City SEZ

    Unauthorised Pakistani cosmetics worth ₹7 lakh seized from Hyderabad’s Nampally and Habeeb Nagar stores

    Unauthorised Pakistani cosmetics worth ₹7 lakh seized from Hyderabad’s Nampally and Habeeb Nagar stores

    FSSAI suspends licence of Delhi-based hospitality establishment for ‘serious non-compliance’

    FSSAI suspends licence of Delhi-based hospitality establishment for ‘serious non-compliance’

    Meet Samrat of Robotic Surgery, poised to bring Dawn of Cutting-edge Healthcare in Bihar

    Meet Samrat of Robotic Surgery, poised to bring Dawn of Cutting-edge Healthcare in Bihar